The preliminary results of Catumaxomab for advanced gastric cancer with peritoneal metastasis is published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
LintonPharm has completed the enrollment of stage 1 of the global phase III trial. This trial evaluates the safety and efficacy of Catumaxomab, a bispecific monoclonal antibody, in adult patients with advanced Gastric Cancer with Peritoneal Carcinomatosis.
The first patient has been dosed in the Phase Ⅰ/Ⅱ clinical trial program for catumaxomab , a monoclonal bispecific antibody being studied for the treatment of Non-Muscle-Invasive Bladder Cancer unresponsive to Bacillus Calmette-Guerin.
NMPA authorized the company to proceed with a Phase Ⅰ/Ⅱ clinical trial evaluating the safety and efficacy of catumaxomab in patients with NMIBC whose tumors have recurred due to Bacillus Calmette-Guerin (BCG) vaccine failure.
Dosing of the first patient with gastric cancer in the stage I of the phase III trial of catumaxomab in Taiwan (China) on 6th October. This global phase III trial is designed to evaluate the safety and efficacy of an intraperitoneal infusion of the catumaxomab in patients with gastric cancer peritoneal carcinomatosis who are not suitable for systemic chemotherapy.